Inhibition of aldose reductase enhances Hela cell sensitivity to chemotherapeutic drugs and involves activation of extracellular signal-regulated kinases

Anti-Cancer Drugs

Volumn 13, Issue 8, 2002, Pages 859-868

  Lee, Eun Kyoung ^a   Regenold, William T ^a   Shapiro, Paul ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Aldose reductase; Chemotherapy; Cytotoxicity; MAP kinase; Polyols

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ALDEHYDE REDUCTASE; ALDOSE REDUCTASE INHIBITOR; ANTINEOPLASTIC AGENT; CISPLATIN; DOXORUBICIN; ETHYL 1 BENZYL 3 HYDROXY 2(5H) OXOPYRROLE 4 CARBOXYLATE; GLUCOSE; MITOGEN ACTIVATED PROTEIN KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; POLYOL; SORBITOL; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER CELL; CANCER RISK; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DIABETES MELLITUS; DRUG ANTAGONISM; DRUG POTENTIATION; DRUG RESISTANCE; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE METABOLISM; HELA CELL; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA;

ALDEHYDE REDUCTASE; CISPLATIN; DOXORUBICIN; ENZYME ACTIVATION; ENZYME INHIBITORS; HELA CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; POLY(ADP-RIBOSE) POLYMERASES; PYRROLIDONECARBOXYLIC ACID;

EID: 0036746965     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200209000-00012     Document Type: Article

References (41)

1. Bando T, Fujimura M, Kasahara K, et al. Exposure to sorbitol induces resistance to cisplatin in human non-small-cell lung cancer cell lines. Anticancer Res 1997; 17: 3345-8.
2. Hyndman D, Flynn T.G. The aldo-keto reductases and their role in cancer. Adv Exp Med Biol 1999; 463: 427-34.
3. Talamini R, Franceschi S, Favero A, et al. Selected medical conditions and risk of breast cancer. Br J Cancer 1997; 75: 1699-703.
4. Weiderpass E, Gridley G, Persson I, et al. Risk of endometrial and breast cancer in patients with diabetes mellitus. Int J Cancer 1997; 71: 360-3.
5. Aloj L, Caraco C, Jagoda E, Eckelman WC, Neumann RD. Glut-1 and hexokinase expression: relationship with 2-fluoro-2-deoxy-d-glucose uptake in A431 and T47D cells in culture. Cancer Res 1999; 59: 4709-14.
6. Behnia K, Boroujerdi M. Inhibition of aldo-keto reductases by phenobarbital alters metabolism, pharmacokinetics and toxicity of doxorubicin in rats. J Pharm Pharmacol 1999; 51: 1275-82.
7. Costantino L, Rastelli G, Vianello P, Cignarella G, Barlocco D. Diabetes complications and their potential prevention: aldose reductase inhibition and other approaches. Med Res Rev 1999; 19: 3-23.
8. Gabbay KH, Merola LO, Field RA. Sorbitol pathway: presence in nerve and cord with substrate accumulation in diabetes. Science 1966; 151: 209-10.
9. Gabbay KH. Role of sorbitol pathway in neuropathy. Adv Metab Disord 1973; 2: 417-32.
10. Greene DA, Stevens MJ, Obrosova I, Feldman EL. Glucose-induced oxidative stress and programmed cell death in diabetic neuropathy. Eur J Pharmacol 1999; 375: 217-23.
11. Kasuya Y, Ito M, Nakamura J, et al. An aldose redutase inhibitor prevents the intimal thickening in coronary arteries of galactose-fed beagle dogs. Diabetologia 1999; 42: 1404-9.
12. Mizuno K, Kato N, Makino M, Suzuki T, Shindo M. Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to improvement of diabetic neuropathy. J Diabetes Complications 1999; 13: 141-50.
13. Graier W. F, Grubenthal I, Dittrich P, Wascher T. C, Kostner G. M. Intracellular mechanism of high d-glucose-induced modulation of vascular cell proliferation. Eur J Pharmacol 1995; 294: 221-9.
14. Vinik AI. Diabetic neuropathy: pathogenesis and therapy. Am J Med 1999; 107: 17-26S.
15. Takahashi M, Fujii J, Miyoshi E, Hoshi A, Taniguchi N. Elevation of aldose reductase gene expression in rat primary hepatoma and hepatoma cell lines: implication in detoxification of cytotoxic aldehydes. Int J Cancer 1995; 62: 749-54.
16. Lewis TS, Shapiro PS, Ahn NG. Signal tranduction through MAP kinase cascades. Adv Cancer Res 1998; 74: 49-139.
17. Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 2000; 275: 39435-43.
18. Kang MJ, Wu X, Ly H, Thai K, Scholey JW. Effect of glucose on stress-activated protein kinase activity in mesangial cells and diabetic glomeruli. Kidney Int 1999; 55: 2203-14.
19. Benes C, Roisin MP, Van Tan H, et al. Rapid activation and nuclear translocation of mitogen-activated protein kinases in response to physiological concentration of glucose in the MIN6 pancreatic beta cell line. J Biol Chem 1998; 273: 15507-13.
20. Tomlinson DR. Mitogen-activated protein kinases as glucose transducers for diabetic complications. Diabetologia 1999; 42: 1271-81.
21. Nishimura C, Matsuura Y, Kokai Y, et al. Cloning and expression of human aldose reductase. J Biol Chem 1990; 265: 9788-92.
22. Lee KW, Ko BC, Jiang Z, Cao D, Chung SS. Overexpression of aldose reductase in liver cancers may contribute to drug resistance. Anti-Cancer Drugs 2001; 12: 129-32.
23. Greene DA, Arezzo JC, Brown MB. Effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy. Zenarestat Study Group. Neurology 1999; 53: 580-91.
24. Ax W, Soldan M, Koch L, Maser E. Development of daunorubicin resistance in tumour cells by induction of carbonyl reduction. Biochem Pharmacol 2000; 59: 293-300.
25. Bando T, Fujimura M, Kasahara K, et al. Exposure to sorbitol induces resistance to cisplatin in human non-small-cell lung cancer cell lines Anticancer Res 1997; 17: 3345-8.
26. Bagnasco SM, Uchida S, Balaban RS, Kador PF, Burg MB. Induction of aldose reductase and sorbitol in renal inner medullary cells by elevated extracellular NaCl. Proc Natl Acad Sci USA 1987; 84: 1718-20.
27. Yancey PH, Burg MB, Bagnasco SM. Effects of NaCl glucose and aldose reductase inhibitors on cloning efficiency of renal medullary cells. Am J Physiol 1990; 258: C 156-63.
28. Sudovtsov VE, Aslanidi AL. Functioning of the sorbitol pathway of glucose metabolism during hibernation. Zh Evol Biokhim Fiziol 1988; 24: 100-3.
29. Storey KB. Metabolism and bound water in overwintering insects. Cryobiology 1983; 20: 365-79.
30. Jeffery J, Jornvall H. Enzyme relationships in a sorbitol pathway that bypasses glycolysis and pentose phosphates in glucose metabolism. Proc Natl Acad Sci USA 1983; 80: 901-5.
31. Stone AA, Chambers TC. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp Cell Res 2000; 254: 110-9.
32. Yeh PY, Chuang SE, Yeh KH, Song YC, Cheng AL. Nuclear extracellular signal-regulated kinase 2 phosphorylates p53 at Thr55 in response to doxorubicin. Biochem Biophys Res Commun 2001; 284: 880-6.
33. Kayali AG, Austin DA, Webster NJ. Stimulation of MAPK cascades by insulin and osmotic shock: lack of an involvement of p38 mitogen-activated protein kinase in glucose transport in 3T3-L1 adipocytes. Diabetes 2000; 49: 1783-93.
34. Guise S, Braguer D, Carles G, Delacourte A, Briand C. Hyperphosphorylation of tau is mediated by ERK activation during anticancer drug-induced apoptosis in neuroblastoma cells. J Neurosci Res 2001; 63: 257-7.
35. Kar S, Carr BI. Growth inhibition and protein tyrosine phosphorylation in MCF 7 breast cancer cells by a novel K vitamin. J Cell Physiol 2000; 185: 386-93.
36. Park SA, Park HJ, Lee BI, et al. Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res Mol Brain Res 2001; 93: 18-26.
37. Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999; 5: 1007-14.
38. Cui W, Yazlovitskaya EM, Mayo MS, Pelling JC, Persons DL. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol Carcinogen 2000; 29: 219-28.
39. Hayakawa J, Ohmichi M, Kurachi H, et al. Inhibition of BAD phosphorylation either at serine 112 via extracellular signal-regulated protein kinase cascade or at serine 136 via Akt cascade sensitizes human ovarian cancer cells to cisplatin. Cancer Res 2000; 60: 5988-94.
40. Zhong J, Troppmair J, Rapp U.R. Independent control of cell survival by Raf-1 and Bcl-2 at the mitochondria. Oncogene 2001; 20: 4807-16.
41. von Gise A, Lorenz P, Wellbrock C, et al. Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals. Mol Cell Biol 2001; 21: 2324-36.